1. CMET-22. CAPMATINIB (INC280) IN METΔEX14-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): EFFICACY DATA FROM THE PHASE 2 GEOMETRY MONO-1 STUDY. (11th November 2019) Authors: Heist, Rebecca S; Seto, Takashi; Han, Ji-Youn; Reguart, Noemi; Garon, Edward B; Groen, Harry J M; Tan, Daniel S W; Hida, Toyoaki; de Jonge, Maja; V Orlov, Sergey; Smit, Egbert F; Souquet, Pierre-Jean; Vansteenkiste, Johan; Le Mouhaer, Sylvie; Robeva, Anna; Waldron-Lynch, Maeve; Giovannini, Monica... Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 6 Page Start: vi56 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single‐arm, phase 2 study. (2nd March 2014) Authors: Wang, Michael; Popplewell, Leslie L.; Collins, Robert H.; Winter, Jane N.; Goy, Andre; Kaminski, Mark S.; Bartlett, Nancy L.; Johnston, Patrick B.; Lister, John; Fanning, Suzanne R.; Tuscano, Joseph M.; Beck, J. Thaddeus; Kaya, Hakan; Robeva, Anna; Fan, Jenna; Klimovsky, Judith; Cheung, Wing; Che... Journal: British journal of haematology Issue: Volume 165:Number 4(2014:May) Page Start: 510 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗